PD-1 Inhibitors Make Impact in Merkel Cell Carcinoma, But Unmet Needs Persist
PD-1 Inhibitors have proved efficacious in approximately half of patients with metastatic MCC, and ongoing research in the field is looking at combination therapies.
Related Articles
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non–Small Cell Lung Cancer
This randomized clinical trial examines whether stereotactic body radiotherapy improves local control compared with hypofractionated conventional radiotherapy.
FDA Grants Priority Review to Durvalumab for Muscle-Invasive Bladder Cancer
The FDA has granted priority review to the sBLA seeking the approval of durvalumab for muscle-invasive bladder cancer.
Frontiers | Cord blood T regulatory cells synergize with ruxolitinib to improve GVHD outcomes
1 Department of Lymphoma/Myeloma, The University of Texas at MD Anderson Cancer Center, Houston, TX, United States 2 Department of Hematology, West China Hospital, Sichuan…
FDA approves cosibelimab-ipdl
On December 13, 2024, the FDA approved cosibelimab-ipdl (Unloxcyt, Checkpoint Therapeutics, Inc.).
Volunteer with the British Society for Haematology
Learn more about how to become a volunteer with BSH and all the work our valuable volunteers create.
FDA Awards Fast Track Designation to LBS-007 for Acute Myeloid Leukemia
LBS-007 receives fast track status from the FDA for use in patients with acute myeloid leukemia.
Home | AML Hub
Online resource for healthcare professionals, providing information, news & support relating to AML
MagnetisMM-3: update on efficacy and safety of less frequent dosing of elranatamab in R/R myeloma
Alexander Lesokhin, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a longer-term update of the safety and efficacy data of less frequent dosing…
NDI-101150 Demonstrates Antitumor Activity, Safety in Heavily Pretreated RCC
NDI-101150 monotherapy demonstrated antitumor activity and was well tolerated among patients with heavily pretreated renal cell carcinoma.
NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer
Fruquintinib plus sintilimab injection has received conditional approval from the NMPA for mismatch repair–proficient advanced endometrial cancer.